Acadia Pharmaceuticals (ACAD) Income towards Parent Company (2010 - 2026)

Acadia Pharmaceuticals' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 80.63% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $148.4 million, a 41.69% decrease from a year earlier, with the FY2025 full-year figure at $163.7 million, down 35.06% from the prior year.
• Income towards Parent Company declined to $3.7 million in Q1 2026 per ACAD's latest filing, from $46.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $169.4 million in Q4 2024 and bottomed at -$113.1 million in Q1 2022.
• The 5-year median for Income towards Parent Company is $16.6 million (2024), against an average of $8.4 million.
• Across the five-year window, Income towards Parent Company sank 139.62% in 2023 and soared 2897.22% in 2024, its largest moves.
• Year by year, Income towards Parent Company stood at -$41.6 million in 2022, then surged by 209.77% to $45.7 million in 2023, then jumped by 270.6% to $169.4 million in 2024, then slumped by 72.66% to $46.3 million in 2025, then sank by 92.05% to $3.7 million in 2026.
• Per Business Quant, the three latest ACAD Income towards Parent Company figures stand at $3.7 million (Q1 2026), $46.3 million (Q4 2025), and $71.8 million (Q3 2025).